Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
View Patent ↗This invention relates to methods of treating stroke by intranasal administration of umbilical cord tissue-derived cells, which are isolated from mammalian umbilical cord tissue substantially free of blood or expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, and do not produce CD117 and/or telomerase. The methods of the invention regenerate, repair and improve neural tissue and improve behavior and neurological function in stroke patients.
1. A method of treating a patient who has had a stroke, the method comprising intranasally administering to the patient umbilical cord tissue-derived cells in an amount effective to treat the stroke, wherein the cells are isolated from mammalian umbilical cord tissue substantially free of blood or are expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture, and wherein the cells do not produce CD117.
2. the method of claim 1 , wherein the umbilical cord tissue-derived cells do not express hTERT or telomerase.
3. The method of claim 1 , wherein the cells further have one or more the following characteristics:
(a) express each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(b) do not express any of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, or HLA-DR,DP,DQ;
(c) secrete at least one of MCP-1, IL-6, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, I309, MDC, and TIMP1
(d) do not secrete at least one of TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF, as detected by ELISA; and
(e) increased expression of interleukin-8; reticulon 1; and chemokine receptor ligand (C-X-C motif) ligand 3, relative to that of a human cell which is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.
4. The method of claim 1 , wherein the stroke is ischemic stroke.
5. The method of claim 1 , wherein the stroke is hemorrhagic stroke.
6. The method of claim 1 , wherein the method further comprises treating the patient with hyaluronidase prior to intranasally administering the cells to the patients.
7. The method of claim 1 , wherein the method further comprises administering an immunosuppressive agent.
8. The method of claim 7 , wherein the immunosuppressive agent is cyclosporine.
9. The method of claim 1 , wherein the cells are administered with at least one other cell type of an astrocyte, oligodendrocyte, neuron, neural progenitor, neural stem cell, genetically engineered cell, or other multipotent or pluripotent stem cell.
10. The method of claim 9 , wherein the at least one other cell type is administered simultaneously with, or before, or after, the umbilical-derived cells.
11. The method of claim 1 , wherein the umbilical cord tissue-derived cells are genetically engineered to produce a gene product that promotes treatment of stroke.
12. The method of claim 1 , wherein the cells exert a trophic effect on the nervous system of the patient.
13. The method of claim 1 , wherein the umbilical cord tissue-derived cells are induced in vitro to differentiate into a neural cell line prior to administration.
14. A method of treating a patient who has had a stroke, the method comprising intranasally administering to the patient a pharmaceutical composition comprising umbilical cord tissue-derived cells in an amount effective to treat the stroke, wherein the cells are isolated from mammalian umbilical cord tissue substantially free of blood or are expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture, and wherein the cells do not produce CD117.
15. The method of claim 14 , wherein the umbilical cord tissue-derived cells do not express hTERT or telomerase.
16. The method of claim 14 , wherein the cells further have one or more the following characteristics:
(a) express each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C;
(b) do not express any of CD31, CD34, CD45, CD80, CD86, CD 117, CD141, CD178, B7-H2, HLA-G, or HLA-DR,DP,DQ;
(c) secrete at least one of MCP-1, IL-6, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, I309, MDC, and TIMP1
(d) do not secrete at least one of TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF, as detected by ELISA; and
(e) increased expression of interleukin-8; reticulon 1; and chemokine receptor ligand (C-X-C motif) ligand 3, relative to that of a human cell which is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.
17. The method of claim 14 , wherein the stroke is ischemic stroke.
18. The method of claim 14 , wherein the stroke is hemorrhagic stroke.
19. The method of claim 14 , wherein the method further comprises treating the patient with hyaluronidase prior to intranasally administering the pharmaceutical compositions to the patients.
20. The method of claim 14 , wherein the pharmaceutical composition further comprises hyaluronidase.
21. The method of claim 14 , wherein the pharmaceutical composition further comprises an immunosuppressive agent.
22. The method of claim 21 , wherein the immunosuppressive agent is cyclosporine.
23. The method of claim 14 , wherein the pharmaceutical composition is administered as a spray, aerosol, gel, solution, emulsion, or suspension.
24. The method of claim 23 , wherein the pharmaceutical composition is administered directly to the upper airways.
25. The method of claim 14 , wherein the pharmaceutical composition is administered directly to the paranasal sinuses.
26. The method of claim 14 , wherein the pharmaceutical composition is administered via a microcatheter.
27. The method of claim 14 , wherein the pharmaceutical composition further comprises at least one other cell type.
28. The method of claim 27 , wherein the at least one other cell type is an astrocyte, oligodendrocyte, neuron, neural progenitor, neural stem cell, genetically engineered cell, or other multipotent or pluripotent stem cell.
29. The method of claim 14 , wherein the umbilical cord tissue-derived cells are genetically engineered to produce a gene product that promotes treatment of stroke.
30. The method of claim 14 , wherein the pharmaceutical composition exerts a trophic effect on the nervous system of the patient.
31. The method of claim 14 , wherein the umbilical cord tissue-derived cells are induced in vitro to differentiate into a neural cell line prior to administration.